Two compounds have attracted serious scientific interest for their effects on mitochondrial health: urolithin A, a metabolite produced when gut bacteria process certain plant polyphenols, and pyrroloquinoline quinone (PQQ), a redox-active compound found in small amounts in some foods. Both are sold as supplements aimed at supporting cellular energy, healthy aging, and physical function — but they work through distinct biological pathways.
Understanding the difference matters if you’re trying to make an informed decision. This article breaks down what the current evidence shows for each compound, where their mechanisms overlap, where they diverge, and what remains genuinely uncertain. Neither compound is a cure for aging or any disease, and the research — while promising — is still maturing.
Key Takeaways
- Urolithin A primarily works through mitophagy — selectively clearing damaged mitochondria — while PQQ works mainly through antioxidant protection and mitochondrial biogenesis stimulation.
- Urolithin A has more and more recent human trial data, including a 2025 placebo-controlled trial showing improvements in age-related immune decline [1].
- PQQ’s human evidence is thinner; most recent research is in cell and animal models, with the main human study dating to 2013 [2].
- The two compounds are not simply redundant — their mechanisms address different aspects of mitochondrial health, which makes combination theoretically plausible but unproven in humans.
- Neither compound has been tested for hard clinical endpoints in large long-term trials, so both remain promising but preliminary from an evidence-based standpoint.
How Urolithin A Works: Cleaning Up Damaged Mitochondria
Urolithin A’s primary mechanism is mitophagy — a selective cellular process that identifies and removes damaged or dysfunctional mitochondria. Think of it as quality control for the cell’s energy-generating machinery. As mitochondria age or accumulate damage, they become less efficient and can release signals that drive inflammation. Mitophagy clears these out, making room for healthier replacements through a process called mitochondrial biogenesis.
A 2024 systematic review of human research confirmed that urolithin A activates this mitophagy pathway and also supports mitochondrial biogenesis, with evidence spanning cell studies, animal models, and early human trials [3]. A randomized, placebo-controlled trial published in Nature Aging in 2025 found that urolithin A supplementation improved age-related immune markers, consistent with mitophagy’s role in clearing exhausted immune cells [1]. Separately, research has shown urolithin A can stimulate mitochondrial biogenesis through estrogen receptor signaling pathways in brain tissue [4].
One complication worth noting: urolithin A is not consumed directly from food in meaningful quantities. It is produced by gut bacteria when you eat pomegranates, walnuts, or certain berries. Significant variation in gut microbiome composition means many people produce little to no urolithin A from diet alone — which is part of the argument for supplementation, though supplement absorption and bioequivalence to endogenously produced urolithin A is still being characterized.
How PQQ Works: Antioxidant Activity and Mitochondrial Signaling
PQQ is a small molecule with potent redox (electron-transferring) activity. It is found in trace amounts in fermented foods, green tea, and some vegetables. Its proposed mitochondrial benefits center on two mechanisms: acting as an antioxidant that protects mitochondrial membranes from oxidative damage, and activating signaling pathways — particularly through PGC-1α — that stimulate mitochondrial biogenesis.
A 2021 review classified PQQ as a ‘vitamin-like’ accessory factor, noting its role in supporting mitochondrial function and its potential relevance to inflammation and disease prevention, while also emphasizing that more human trial data is needed [5]. A 2013 human study found that dietary PQQ supplementation altered inflammation markers and indicators of mitochondrial-related metabolism in healthy subjects [2]. More recent research has shown PQQ protecting mitochondrial function in cells undergoing premature senescence [6] and reducing mitochondrial damage in radiation-injury models via a MOTS-c-dependent pathway [7].
Unlike urolithin A, PQQ does not induce mitophagy in the same way. Its primary angle is protecting existing mitochondria from damage and promoting new mitochondrial growth — without the selective degradation step that characterizes urolithin A’s mechanism.
Where the Mechanisms Overlap and Where They Differ
Both compounds ultimately aim at improving mitochondrial quantity and quality, but they approach the problem from different directions. Urolithin A triggers the removal of damaged mitochondria first, then supports replacement with healthier ones. PQQ focuses more on protecting mitochondria from oxidative stress and directly stimulating new mitochondrial production. In that sense, they are not simply redundant — urolithin A is more of a ‘clearance’ agent and PQQ more of a ‘protection and growth’ agent.
Both compounds appear to influence mitochondrial biogenesis through overlapping signaling pathways, including PGC-1α activation, though the upstream triggers differ. Urolithin A engages autophagy machinery (specifically the p62/SQSTM1 pathway, as demonstrated in neurodegeneration research [8]), while PQQ appears to work more directly on redox signaling and cellular energy sensing.
For muscle health specifically, a 2024 Sports Medicine review noted that mitochondrial quality is a key target for preserving physical function with age, and that compounds supporting both mitophagy and biogenesis may be complementary rather than interchangeable [9]. This suggests the two compounds might theoretically act on different parts of the same problem — though head-to-head human trials comparing them directly do not yet exist.
What the Human Evidence Actually Shows
Urolithin A has the larger and more recent body of controlled human trial data. The 2025 Nature Aging trial demonstrated improvements in age-related immune decline, including enhanced mitophagic activity in immune cells, in a placebo-controlled design [1]. The 2024 systematic review identified multiple human studies showing effects on muscle endurance, mitophagy biomarkers, and cellular health markers [3]. Animal and cell research extends to contexts including retinal neurodegeneration [8], cognitive protection [4], and cancer immunology [10].
PQQ’s human evidence is thinner but real. The most-cited human study dates to 2013 and showed changes in inflammation and mitochondrial metabolism markers after dietary PQQ [2]. More recent work has focused on cell and animal models — including stem cell mitochondrial preservation [11] and neuroprotective effects in preclinical models of neurodegenerative disease [12] — but large, well-powered human trials are lacking. This is an honest gap in the literature.
Neither compound has been tested in a large-scale, long-term randomized controlled trial for hard endpoints like mortality, cardiovascular events, or functional independence. The evidence for both is promising but preliminary when held to that standard.
Potential Use Cases: Are They Targeting the Same People?
The research profiles suggest somewhat different primary use cases, at least based on where the evidence is strongest so far. Urolithin A has the most evidence in the contexts of age-related muscle decline, immune aging, and mitophagy induction — making it potentially relevant for older adults concerned about physical function, immune resilience, or cellular aging more broadly [3][1].
PQQ’s evidence points more toward antioxidant protection, cognitive support in neurodegenerative contexts, and mitochondrial preservation in stress or damage scenarios [12][7]. The ‘vitamin-like’ framing in the literature suggests PQQ may be more relevant as a daily nutritional support compound rather than a targeted therapeutic [5].
Some supplement formulators combine the two compounds on the rationale that their mechanisms are complementary — clearance plus protection. This is theoretically coherent, but there are no published human studies testing the combination specifically, so the additive or synergistic claim remains speculative.
Safety and Practical Considerations
Urolithin A has been evaluated in human trials at doses ranging from 250 mg to 2000 mg per day, with no serious adverse events reported in published studies to date [3][1]. It is generally described as well-tolerated. PQQ has also shown a reasonable short-term safety profile in the available human research at typical supplemental doses (10–20 mg/day), though the 2013 study was relatively small and short-duration [2].
Long-term safety data for both compounds in large, diverse populations is still limited. Neither compound has established official recommended dietary intake levels or approved medical uses. People with chronic health conditions, those taking medications that affect cellular metabolism or immune function, and pregnant or breastfeeding individuals should consult a healthcare provider before using either supplement.
🛒 Where to Buy Urolithin A
- Timeline Mitopure SoftgelsClinically studied
softgels, 500 mg/day — The clinically studied form (Amazentis); used in the human trials. - Pure Encapsulations Renual
caplique capsules, 250 mg Mitopure Urolithin A/serving (with resveratrol + CoQ10) — established clinical-supplement brand, third-party tested. - ProHealth Longevity Urolithin A
capsules, 500 mg — Longevity-focused brand, often higher dose. - Double Wood Urolithin A
capsules, 250-500 mg — Budget-friendly, widely available, COA on request.
As an Amazon Associate we earn from qualifying purchases. Prices and availability vary; verify dose and third-party testing before buying.
A Note on the Evidence
The evidence for both urolithin A and PQQ, while growing, is based on studies that are mostly short-term, small in scale, or conducted in cell and animal models — neither compound has established long-term safety data or proven clinical benefits for any medical condition. This article is for informational purposes only and does not constitute medical advice; consult a qualified healthcare provider before adding any new supplement to your routine, particularly if you are pregnant, have a chronic health condition, or take medications.
Frequently Asked Questions
What is the main difference between urolithin A and PQQ?
Urolithin A primarily triggers mitophagy — the selective removal of damaged mitochondria — before supporting new mitochondrial growth [3]. PQQ works mainly as a redox-active antioxidant that protects mitochondria from oxidative damage and stimulates mitochondrial biogenesis through different upstream signals [5]. They target related but distinct aspects of mitochondrial quality control.
Which compound has stronger human evidence?
Urolithin A currently has the more robust human trial evidence, including a 2024 systematic review of human studies [3] and a 2025 randomized, placebo-controlled trial published in Nature Aging [1]. PQQ’s most directly relevant human study was published in 2013 [2], and more recent research has largely been in cell cultures or animal models.
Can urolithin A and PQQ be taken together?
There is no published human research testing the combination directly. The mechanisms are theoretically complementary — urolithin A clears damaged mitochondria while PQQ may protect and grow healthy ones — but any claim of synergistic benefit in humans is speculative at this stage. It is reasonable to discuss combination use with a healthcare provider.
Does PQQ have antioxidant benefits beyond mitochondria?
PQQ has broad redox activity and has been studied for anti-inflammatory effects and neuroprotective properties beyond mitochondria specifically. A 2021 review described it as having relevance to health and disease prevention through multiple mechanisms [5], and 2025 research explored its role in neurodegenerative disease models [12]. However, most of this research is preclinical.
Why can't most people get enough urolithin A from food?
Urolithin A is not present in food directly — it is produced by gut bacteria that metabolize precursor compounds called ellagitannins found in pomegranates, walnuts, and some berries. Substantial individual variation in gut microbiome composition means many people produce very little urolithin A even with adequate dietary precursor intake, which is one rationale for direct supplementation [3].
Are there any known safety concerns with either supplement?
Both compounds have shown acceptable short-term safety profiles in published research at typical supplemental doses, with no serious adverse events reported in urolithin A trials [1] and no significant concerns noted in the primary PQQ human study [2]. Long-term safety data in large populations is lacking for both. Anyone with chronic health conditions or taking prescription medications should consult a doctor before starting either supplement.
References
- Denk D et al. Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial. Nature aging (2025). PMID 41174221
- Harris CB et al. Dietary pyrroloquinoline quinone (PQQ) alters indicators of inflammation and mitochondrial-related metabolism in human subjects. The Journal of nutritional biochemistry (2013). PMID 24231099
- Kuerec AH et al. Targeting aging with urolithin A in humans: A systematic review. Ageing research reviews (2024). PMID 39002645
- Chen P et al. Urolithin A protects against domoic acid-induced cognitive deficits via promoting estrogen receptor-α-mediated mitochondrial biogenesis signaling in mice. Free radical biology & medicine (2025). PMID 40818743
- Jonscher KR et al. Pyrroloquinoline-Quinone Is More Than an Antioxidant: A Vitamin-like Accessory Factor Important in Health and Disease Prevention. Biomolecules (2021). PMID 34680074
- Gao Y et al. Pyrroloquinoline quinone (PQQ) protects mitochondrial function of HEI-OC1 cells under premature senescence. npj aging (2022). PMID 35927260
- Zhang Y et al. Pyrroloquinoline Quinone Alleviates Mitochondria Damage in Radiation-Induced Lung Injury in a MOTS-c-Dependent Manner. Journal of agricultural and food chemistry (2024). PMID 39259217
- Jiménez-Loygorri JI et al. Urolithin A promotes p62-dependent lysophagy to prevent acute retinal neurodegeneration. Molecular neurodegeneration (2024). PMID 38890703
- Broome SC et al. Mitochondria as Nutritional Targets to Maintain Muscle Health and Physical Function During Ageing. Sports medicine (Auckland, N.Z.) (2024). PMID 39060742
- Denk D et al. Expansion of T memory stem cells with superior anti-tumor immunity by Urolithin A-induced mitophagy. Immunity (2022). PMID 36351375
- Liu S et al. Pyrroloquinoline quinone promotes human mesenchymal stem cell-derived mitochondria to improve premature ovarian insufficiency in mice through the SIRT1/ATM/p53 pathway. Stem cell research & therapy (2024). PMID 38581065
- Xie T et al. Current study on Pyrroloquinoline quinone (PQQ) therapeutic role in neurodegenerative diseases. Molecular biology reports (2025). PMID 40234255
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.